IBA Delivers Strong FY 2025 Results with Solid Execution in All Segments

Why It Matters

The results demonstrate IBA’s expanding foothold in the fast‑growing proton‑therapy and nuclear‑medicine markets, providing cash flow and visibility for continued R&D and strategic acquisitions. Investors see stronger earnings, a robust order pipeline, and a healthier balance sheet, reinforcing the firm’s leadership in particle‑accelerator technology.

Key Takeaways

• Revenue up 24% to €620 M (~$682 M).
• Adjusted EBIT up 58% to €27.4 M (~$30 M).
• Order intake record €452 M (~$497 M).
• Backlog hits €1.6 B (~$1.76 B) all‑time high.
• Refinancing package €125 M (~$138 M) strengthens balance sheet.

Pulse Analysis

IBA’s FY 2025 performance underscores the accelerating demand for particle‑accelerator solutions, especially in proton‑therapy where hospitals are expanding treatment capacity. The 44% sales jump in the Clinical division reflects a broader shift toward high‑precision cancer care, positioning IBA ahead of competitors that rely on legacy equipment. By converting a sizable backlog into revenue, the firm secures multi‑year visibility, a critical advantage in a capital‑intensive market where equipment lifecycles span a decade.

Financially, the company balanced higher sales with a modest dip in gross margin, a consequence of legacy low‑margin projects offset by productivity gains. Nevertheless, adjusted EBIT and net profit surged, driven by disciplined operating expenses that remained at 28% of sales. The €125 million (≈$138 million) refinancing deal not only lowered financing costs but also aligned working‑capital with strategic investments, enhancing cash‑flow resilience. With net debt trimmed to €58 million (≈$64 million) after the ORA acquisition, IBA is well‑positioned to fund future growth without over‑leveraging.

Strategically, the acquisition of ORA expands IBA’s footprint in radiochemistry, complementing its existing nuclear‑medicine portfolio and tapping into the burgeoning market for radiopharmaceuticals. The launch of the PanTera 225 Ac production facility signals a commitment to supply chain robustness for clinical trials and compassionate use. Looking ahead, the company’s FY 2026 adjusted EBIT target of €32 million and a proposed €0.25 dividend per share signal confidence in sustained profitability, while the share‑buyback program offers additional shareholder return mechanisms. These moves collectively reinforce IBA’s leadership in a sector poised for continued expansion.